REVB REVELATION BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1810560 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.6%
TTM EPS YoY122.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-133.4%
ROA-106.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.98x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-18.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.51M | $1.92M | $1.38M | $964,190 | $922,857 | $1.32M | $858,830 | $605,504 |
| SG&A expense | $1.87M | $1.74M | $1.72M | $1.61M | $1.02M | $1.14M | $1.24M | $1.15M |
| Operating income | -$3.38M | -$3.66M | -$3.09M | -$2.57M | -$1.94M | -$2.46M | -$2.09M | -$1.75M |
| Income tax | $0 | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.32M | -$3.32M | -$3.01M | -$2.51M | -$1.91M | -$2.44M | -$2.05M | -$1.73M |
| EBITDA | -$3.38M | -$3.65M | -$3.09M | -$2.57M | -$1.94M | -$2.45M | -$2.09M | -$1.75M |
| EPS (basic) | -5.92 | -0.87 | -2.71 | — | -49.51 | -28.04 | -25.34 | — |
| EPS (diluted) | -5.92 | -0.87 | -2.71 | — | -49.51 | -28.04 | -25.34 | — |
| Weighted avg. shares (diluted) | 559,596 | 3.83M | 3.21M | — | 94,455 | 200,668 | 80,943 | — |
| Banking | ||||||||
| Net interest income | $68,063 | $82,159 | — | — | $35,512 | $19,672 | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.12M | $11.48M | $14.11M | $10.70M | $12.71M | $5.17M | $3.70M | $6.50M |
| Current assets | $9.27M | $11.68M | $14.21M | $10.81M | $12.83M | $5.36M | $3.93M | $6.57M |
| PP&E, net | $163,847 | $172,032 | $140,717 | $18,067 | $23,919 | $35,170 | $42,390 | $56,332 |
| Total assets | $10.02M | $12.50M | $15.04M | $11.58M | $12.86M | $5.40M | $3.97M | $6.62M |
| Current liabilities | $2.33M | $1.88M | $1.42M | $2.00M | $1.85M | $1.57M | $1.09M | $1.91M |
| Total liabilities | $2.79M | $2.43M | $2.06M | $2.72M | $1.85M | $1.57M | $1.09M | $1.91M |
| Shareholders' equity | $7.23M | $10.07M | $12.99M | $8.86M | $11.00M | $3.83M | $2.88M | $4.71M |
| Shares outstanding | 683,442 | 3.91M | 3.91M | 226,330 | 3.59M | 1.53M | 963,796 | 43,526 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.36M | -$2.56M | -$3.21M | -$1.97M | -$1.59M | -$1.92M | -$2.79M | -$3.75M |
| Capital expenditure | $0 | $39,628 | $71,879 | — | — | — | — | -$17,689 |
| Free cash flow | -$2.36M | -$2.60M | -$3.29M | — | — | — | — | -$3.73M |
| Investing cash flow | $0 | -$39,628 | -$71,879 | — | — | — | — | $17,689 |
| Financing cash flow | $0 | -$33,802 | $6.70M | -$41,166 | $9.12M | — | — | $3.69M |
| Depreciation & amortization | $8,185 | $8,313 | $7,203 | $5,852 | $6,765 | $7,220 | $7,221 | $7,221 |
| Stock-based compensation | $482,229 | $401,417 | $470,997 | $370,166 | $874 | $873 | $223,455 | $72,566 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.